^
    9d
    BREASTIMMU02: Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2+ Breast Cancer Breast Cancer (clinicaltrials.gov)
    P2, N=90, Active, not recruiting, Centre Leon Berard | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 amplification
    |
    Herceptin (trastuzumab) • paclitaxel • Neulasta (pegfilgrastim)
    15d
    BREASTIMMU02: Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2+ Breast Cancer Breast Cancer (clinicaltrials.gov)
    P2, N=90, Recruiting, Centre Leon Berard | Trial completion date: Sep 2025 --> Sep 2027 | Trial primary completion date: Jan 2025 --> Jan 2027
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 amplification
    |
    Herceptin (trastuzumab) • paclitaxel • Neulasta (pegfilgrastim)
    2ms
    RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy (clinicaltrials.gov)
    P2, N=35, Not yet recruiting, City of Hope Medical Center
    New P2 trial
    |
    Fotivda (tivozanib) • sturlimogene erparepvec (RP2)
    2ms
    RMS13: Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy (clinicaltrials.gov)
    P2, N=115, Active, not recruiting, St. Jude Children's Research Hospital | Trial primary completion date: Jul 2025 --> Dec 2025
    Trial primary completion date
    |
    Avastin (bevacizumab) • sorafenib • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • irinotecan • vincristine • dactinomycin • Neulasta (pegfilgrastim) • Neupogen (filgrastim) • dexrazoxane
    2ms
    ANC-IIT-004: Clinical Study of Thiopegfilgrastim for Preventing Bone Marrow Suppression in Thoracic Tumor Chemoradiotherapy (clinicaltrials.gov)
    P2, N=30, Recruiting, Affiliated Hospital of Nantong University
    New P2 trial
    |
    HHPG-19K (mecapegfilgrastim)
    2ms
    GCSF-PAIN: G-CSF-Induced Bone Pain and Supportive Care Approaches (clinicaltrials.gov)
    P=N/A, N=128, Recruiting, Ankara Etlik City Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Neulasta (pegfilgrastim) • Lonquex (lipegfilgrastim) • Neupogen (filgrastim)
    2ms
    Allogeneic, Antigen-Presenting, GM-CSF-secreting, SV-BR-1-GM Whole Cell-Therapeutic Vaccine and Immunotherapy: A Phase I Pilot Safety and Feasibility Study for Solid Tumor Patients With CNS Metastases (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, Medical College of Wisconsin
    New P1 trial
    |
    Keytruda (pembrolizumab) • cyclophosphamide • Bria-IMT (SV-BR-1-GM) • ViraferonPeg (peginterferon-α-2b)
    2ms
    GCSF-PAIN: G-CSF-Induced Bone Pain and Supportive Care Approaches (clinicaltrials.gov)
    P=N/A, N=128, Not yet recruiting, Ankara Etlik City Hospital
    New trial
    |
    Neulasta (pegfilgrastim) • Lonquex (lipegfilgrastim) • Neupogen (filgrastim)
    3ms
    Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC (clinicaltrials.gov)
    P2, N=60, Recruiting, Replimune Inc. | N=30 --> 60
    Enrollment change
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • Imfinzi (durvalumab) • sturlimogene erparepvec (RP2)
    4ms
    Aortitis after granulocyte-colony stimulating factor administration: A case report. (PubMed, Biomed Rep)
    In the present study, the case of a 59-year-old man is presented who received chemotherapy (eribulin) for liver metastases from sacral chordoma and subsequently developed acute aortitis after the administration of G-CSF...After discontinuing the antibiotics, the patient was monitored closely without further treatment. His condition improved within a few days; therefore, it was concluded that aortitis was induced by G-CSF.
    Journal
    |
    CRP (C-reactive protein)
    |
    Halaven (eribulin mesylate) • Neulasta (pegfilgrastim)
    4ms
    A Trial of HHPG-19K Injection and Auto-HHPG-19K Injection in Prevention of Chemotherapy-related Moderate to Severe Neutropenia of Patients With Nonmyeloid Malignancies (clinicaltrials.gov)
    P3, N=0, Withdrawn, Jiangsu HengRui Medicine Co., Ltd. | N=107 --> 0 | Trial completion date: Jun 2024 --> Jul 2025 | Not yet recruiting --> Withdrawn | Trial primary completion date: May 2024 --> Jul 2025
    Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date
    |
    HHPG-19K (mecapegfilgrastim)
    4ms
    RPx: A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3 (clinicaltrials.gov)
    P=N/A, N=50, Not yet recruiting, Replimune Inc. | Initiation date: Jun 2025 --> Nov 2025
    Trial initiation date
    |
    RP3 • Tudriqev (vusolimogene oderparepvec-wtpg) • sturlimogene erparepvec (RP2)